Walleye Capital LLC purchased a new stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) during the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 200,968 shares of the biopharmaceutical company’s stock, valued at approximately $420,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $43,000. Bank of Montreal Can bought a new position in shares of Lexicon Pharmaceuticals in the 1st quarter valued at $26,000. GSA Capital Partners LLP acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $124,000. SG Americas Securities LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 69.9% during the 1st quarter. SG Americas Securities LLC now owns 33,720 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 13,876 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at $186,000.
Insider Transactions at Lexicon Pharmaceuticals
In other Lexicon Pharmaceuticals news, Director International S.C.A. Artal acquired 16,173,800 shares of the stock in a transaction dated Monday, August 1st. The stock was purchased at an average cost of $2.50 per share, with a total value of $40,434,500.00. Following the transaction, the director now owns 48,433,261 shares in the company, valued at approximately $121,083,152.50. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.50% of the company’s stock.
Lexicon Pharmaceuticals Stock Down 3.3 %
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Citigroup raised their price objective on Lexicon Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, July 1st. Piper Sandler assumed coverage on Lexicon Pharmaceuticals in a report on Friday, August 12th. They set an “overweight” rating and a $10.00 price objective on the stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.